scholarly journals THE STOMA REVERSAL AFTER HARTMANN PROCEDURE IN PATIENTS WITH COLORECTAL CANCER OPERATED IN EMERGENCY

2020 ◽  
Vol 2 (1) ◽  
pp. 25-29
Author(s):  
Georgiana Bianca Constantin ◽  
D. Firescu ◽  
D. Voicu ◽  
B. Ștefănescu ◽  
R. Mihailov ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Morbidity Rate ◽  
Hartmann Procedure ◽  
Important Place ◽  
Stoma Reversal ◽  
Hartmann Reversal ◽  
Very High ◽  
Clinical Emergency ◽  
Hartmann Operation

The Hartmann procedure still has an important place in the surgical therapy of complicated colorectal cancers. The morbidity rate can be very high and many patients never undergo the stoma reversal. We conducted a retrospective study on 431 patients with colorectal cancer operated in the second clinic of General Surgery of the Clinical Emergency County Hospital Galati between 2008-2017. 42,53 % of the patients with Hartmann operation had a stoma reversal after a medium period of 5,7 months. The 5-years survival rate in patients with stoma reversal was 4,9 %. The reversal rate in our study is similar to those found in the literature in recent studies, that report percentages of 23,3 %-55,17 %. In our study, the medium period between the emergency Hartmann procedure and the reversal of the stoma was 5,7 months, which is also similar to the data in the literature. We found a 5-years survival rate of 4,9 % in patients with Hartmann reversal, much lower than others’ results. Many stomas initially intended to be temporary, may not be reversed. It is important to optimize the timing of stoma closure. A period of approximately 6 months between the initial operation and the reversal seem to be adequate.

scholarly journals Trajectories of sickness absence and disability pension in colorectal cancer: a Swedish cohort study

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
L Chen ◽  
K Alexanderson
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Sickness Absence ◽  
Educational Level ◽  
Disability Pension ◽  
Population Based ◽  
Work Situation ◽  
Working Age ◽  
Future Work ◽  
Very High

Abstract Background Working-aged colorectal cancer (CRC) patients have a much better survival nowadays, indicating the importance of their future work situation. We aimed to investigate trajectories of sickness absence and disability pension (SADP) days before and after CRC diagnosis and in references, and risk factors associated with different trajectories. Methods A longitudinal, population-based matched cohort study of 4735 CRC survivors in Sweden aged 19-62 when first diagnosed with CRC in 2008-2011, and 18,230 matched references was conducted, using microdata linked from several nationwide registers. The annual SADP net days for 2 years before through 5 years after diagnosis date were computed. A group-based trajectory model was used to depict SADP trajectories. Associations between trajectory membership, and sociodemographic and clinical variables were tested by chi2 test and multinomial logistic regression. Results Four trajectories of SADP days/year for CRC survivors were identified: “only increase around diagnosis” (52% of all, n = 2481), “slight increase after diagnosis” (27%), “high then decrease moderately after diagnosis” (13%), and “constantly very high” (8%). Educational level (R2=0.022), Charlson's Comorbidity Index (R2=0.029), and prediagnostic mental disorders (R2=0.066) were the strongest factors determining the SADP trajectory groups. In references, three trajectories (”constantly low” (80% of all), “constantly moderate and decrease gradually” (12%), and “very high then decrease overtime” (8%)) were identified. Conclusions Approximately 80% of CRC survivors return to a low level of SADP (0-60 days/year) at 5 years postdiagnosis. Prediagnostic status of mental disorders, somatic comorbidity, and low educational level are good indicators of future high SADP levels for CRC survivors. Key messages Most of working-age colorectal cancer survivors have low levels of sickness absence and disability pension days five years after their diagnosis. Trajectory analyses based on population-based register data can be used as a good approach in understanding future work situation regarding sick leave among working-age cancer survivors.

scholarly journals Carbon Ion Radiotherapy for Oligo-Recurrence in the Lung

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Naoyoshi Yamamoto ◽  
Mio Nakajima ◽  
Hirohiko Tsujii ◽  
Tadashi Kamada
Keyword(s):  
Colorectal Cancer ◽  
Lung Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Local Control ◽  
Local Control Rate ◽  
Carbon Ion Radiotherapy ◽  
Overall Survival Rate ◽  
Carbon Ion ◽  
Metastatic Lung

The clinical results after carbon ion radiotherapy for the metastatic lung tumors believed to be in the state of oligo-recurrence were evaluated. One hundred and sixteen lesions in 91 patients with lung cancer metastasis were treated with carbon ion radiotherapy at our institute from April 1997 to February 2011. Regarding the prescribed dose, total dose ranged between 40 gray equivalents (GyE) and 80 GyE, and fraction size ranged from 1 to 16 fractions. After a median followup period of 2.3 years (range, 0.3–13.1 years), the statistical overall survival rate and local control rate were 71.2% and 91.9% at 2 years after treatment, respectively. Treatment-related side effects were not a clinical problem. When classified by the primary organ, there were 49 cases of lung cancer, 20 cases of colorectal cancer, and 22 cases of others. The overall survival rate and local control rate for lung metastasis cases from lung cancer at 2 years after treatment were 81.5% and 92.4%, respectively, and 65.0% and 92.0% regarding lung metastasis from colorectal cancer. Carbon ion beam therapy for the metastatic lung tumors is a safe therapy, and the therapeutic effect is comparable to the outcome obtained from reported surgical resections.

scholarly journals The Effect of miR-145-5p, DANCR and NRAS Expression Levels on the Survival Rate of Colorectal Cancer Patients

2021 ◽  
Vol 22 (12) ◽  
pp. 4043-4049
Author(s):  
Fatemeh Bahreini ◽  
Masoud Saidijam ◽  
Saeid Afshar ◽  
Zahra Mousivand ◽  
Rezvan Najafi
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Expression Levels ◽  
Colorectal Cancer Patients

scholarly journals Case Report: Carcinoma of Colon

2018 ◽  
Vol 4 (1) ◽  
pp. 1-3
Author(s):  
sushila ladumor ◽  
Adham Darweesh
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Survival Rate ◽  
Gastrointestinal Tract ◽  
Colorectal Carcinoma ◽  
Surgical Resection ◽  
Early Stage ◽  
Occult Lesion ◽  
Carcinoma Of Colon ◽  
Ct And Mri

Colorectal cancer is a disease that is curable if diagnosed at early stage and also it is preventable if predisposing adenomas are detected and removed. Colorectal Carcinoma (CRC) is commonest malignancy of the gastrointestinal tract and is the second most usually diagnosed cancer in adults, mainly at 6th to 7th decades of life[2]. CT and MRI are the modalities of choice used for staging. Colonoscopy for better evaluation and tissue diagnosis as well as to see other occult lesion. Surgical resection may be curative although five-year survival rate is 40 - 50 %.

scholarly journals A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-8
Author(s):  
Lydia M. Dreosti ◽  
Alicia McMaster ◽  
Rashem Mothilal
Keyword(s):  
Colorectal Cancer ◽  
South Africa ◽  
Survival Rate ◽  
Metastatic Colorectal Cancer ◽  
Chemotherapy Regimen ◽  
Stage Iv ◽  
Sensory Neuropathy ◽  
Therapeutic Management ◽  
First Line ◽  
Open Label

Oxaliplatin is a standard first-line treatment for metastatic colorectal cancer. The objectives were to document the therapeutic management of oxaliplatin in South Africa, determine the incidence and severity of sensory neuropathy, and record the 2-year survival rate. Meccelox was a prospective, noncontrolled, open label, multicentre, observational survey of adult patients with stage IV metastatic colorectal cancer treated with oxaliplatin-based chemotherapeutic regimens. The study was conducted from August 2007 to November 2011 in 29 sites in South Africa by 66 participating treating physicians. Among the 195 enrolled patients, 61% were treated with FOLFOX regimen (5-fluorouracil/folinic acid plus oxaliplatin) for an average of 12 cycles and 32% patients were treated with XELOX (capecitabine plus oxaliplatin) for an average of 6–8 cycles, with the main reason for discontinuation being completion of the preplanned prescribed regimen. In Meccelox survey, 80% of patients were treated with intent of palliation. Overall 64% of patients reported symptoms of sensory neuropathy. The 2-year survival rate was 30%. Conclusions. Patients received a specified preplanned number of chemotherapy cycles rather than being treated until disease progression or toxicity. Both the incidence of neuropathy and the 2-year survival rate were less than previous reports.

The Regulatory Role of Both MBNL1 and MBNL1-AS1 in Several Common Cancers

2021 ◽  
Vol 27 ◽  
Author(s):  
Qi Zhang ◽  
Yinxin Wu ◽  
Jinlan Chen ◽  
Yuxuan Cai ◽  
Bei Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Lung Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Rna Splicing ◽  
Metabolic Regulation ◽  
Overall Survival Rate

Background: MBNL1, a protein encoded by q25 gene on chromosome 3, belongs to the tissue-specific RNA metabolic regulation family, which controls RNA splicing.[1]MBNL1 formed in the process of development drive large transcriptomic changes in cell differentiation,[2] it serves as a kind of tumor differentiation inhibitory factor.MBNL1 has a close relationship with cancer, comprehensive analysis, [3]found that breast cancer, leukemia, stomach cancer, esophageal adenocarcinoma, glial cell carcinoma and another common tumor in the cut, and cut in Huntington's disease. But MBNL1 plays a promoting role in cervical cancer, is contradictory in colorectal cancer, It promotes colorectal cancer cell proliferation, On the other hand, it inhibits its metastasis, so it is an important physiological marker in many cancers. When we integrated the role of MBNL1 protein in various tumors, we found that its antisense RNA, MBNL1-AS1, had a good inhibitory effect in several colorectal cancer, non-small cell lung cancer, and gastric cancer. Objective: To elucidate the expression of MBNL1 and MBNL1-AS1 in various tumors, and to search for their physiological markers. Methods: It was searched by the PUMUB system and summarized its expression in various cancers. Results: MBNL1 was down-regulated, leukemia, breast cancer, glioblastoma, gastric cancer, overall survival rate, recurrence, metastasis increased. While the metastasis of colon cancer decreased, proliferation was promoted, and the effect of both was promoted for cervical cancer.MBNL1-AS1 was down-regulated, and the overall survival rate, recurrence, and metastasis of lung cancer, colorectal cancer, and bladder cancer increased. Conclusion: MBNL1 may be an important regulator of cancer, and MBNL1-AS1 is a better tumor suppressor.

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis

2022 ◽  
Author(s):  
Chunhui Jin ◽  
Xiaodan Zhu ◽  
Xiaona Huang ◽  
Tingjie Gong ◽  
Zhipeng Wei ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Mismatch Repair ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Objective Response ◽  
Progression Free Survival ◽  
Adverse Event Rate ◽  
Efficacy And Safety ◽  
Deficient Mismatch Repair

Aims: To evaluate the efficacy and safety of PD-1/PD-L1 and/or CTLA-4 inhibitors in the treatment of colorectal cancer (CRC) by meta-analysis. Methods: Electronic databases were searched. Eligible studies included investigations of efficacy and safety of anti-PD-1/PD-L1 or anti-CTLA-4 agents in patients with CRC. Corresponding indicators were calculated. Results: A total of 15 articles were included. The pooled objective response rate, overall survival rate, progression-free survival rate and adverse event rate were 33, 56, 46 and 59%, respectively. The objective response rates for CRC with deficient mismatch repair and CRC with proficient mismatch repair were 43 and 3%, respectively, in patients treated with PD-1 inhibitors. Conclusion: The authors' study indicates that PD-1/PD-L1 inhibitors manifest promising clinical responses in the treatment of CRC with deficient mismatch repair with acceptable treatment-related adverse events.

Young Firms Sustainability and Corporate Reputation

2017 ◽  
pp. 1-27 ◽  
Author(s):  
Domenico Nicolò
Keyword(s):  
Survival Rate ◽  
Corporate Reputation ◽  
Survival Rates ◽  
Entrepreneurial Experience ◽  
Young Firms ◽  
Size Classes ◽  
The Usa ◽  
Different Characteristics ◽  
Very High

Although young firms are very vulnerable, significant differences emerge by comparing the survival rates of the companies in the first stage of life in different countries and industries, of different sizes, and with different characteristics of the leader (team of co-founders): education, previous entrepreneurial experience, reputation, etc. Many variables influence the performance of the companies and their chances of survival. Each enterprise is a singularity. Thus, it is methodologically wrong and naive any attempt to define ideal models and general “recipes” to reduce the vulnerability of the young firms. This hypothesis is confirmed by the analysis of the survival rates of the young firms born in the USA and in EU. The variance of the five-year survival rate is very high by comparing companies from different nations, of different size classes, those operating in different industries, and those whose leaders have or not have any previous entrepreneurial experience. The lack of corporate reputation is the only weakness common to the young firms. Since these companies do not have a history that can prove their ability to satisfy their commitments toward the stakeholder, they haven't a reputation and therefore are very weak their bonds of trust with stakeholders. The first difficulty, these weak bonds of trust are broken and young businesses collapse in on themselves. To achieve sustainability, young firms must quickly build a corporate reputation to strengthen the bonds of trust with the stakeholders. By this way, they will be more resistant to the difficulties. This is the only effective general “recipes”. (Nicolò 2015; Nicolò & Ferrara 2015).

CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients

2019 ◽  
Vol 51 (3) ◽  
pp. 844-849 ◽  
Author(s):  
Shafigheh Asgari-Karchekani ◽  
Mohammad Karimian ◽  
Tahereh Mazoochi ◽  
Maryam Akhavan Taheri ◽  
Tahereh Khamehchian
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Protein Expression ◽  
Pathological Characteristics

scholarly journals Effects of Site, Genotype and Subsequent Harvest Rotation on Willow Productivity

Agriculture ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 412 ◽  
Author(s):  
Mariusz Jerzy Stolarski ◽  
Michał Krzyżaniak ◽  
Dariusz Załuski ◽  
Józef Tworkowski ◽  
Stefan Szczukowski
Keyword(s):  
Survival Rate ◽  
Plant Height ◽  
Biomass Yield ◽  
High Impact ◽  
The Other ◽  
Plant Survival ◽  
Dry Biomass ◽  
The Mean ◽  
Very High ◽  
Biometric Features

Perennial crops harvested in short rotations provide substantial amounts of biomass. This study determined the survival rate, biometric features and yield of fresh and dry biomass of 15 willow genotypes (including seven varieties and eight clones), cultivated at two different sites in two consecutive three-year harvest rotations. The study revealed the very high impact of the genotype (81% of the total variance) on the willow yield. The harvest rotation, along with the genotype, had a significant impact on the plant survival rate and the number of shoots per stool. Willow biomass was mainly affected by the plant height, its survival rate and shoot diameter. The significantly highest fresh (106 Mg ha−1) and dry biomass yield (54.0 Mg ha−1) was obtained from the Żubr variety of S. viminalis, which distinguished this variety from the other genotypes. The mean yield for the best three and five genotypes was 13% and 17% lower, respectively, and the mean yield for the whole experiment was 37% lower compared to the mean yield of the best variety (Żubr). Therefore, the choice of a willow genotype is of key importance for successful willow production.

Sign in / Sign up

Export Citation Format

Share Document